4 Data represented as event rates over a median follow-up of 18.2 months
Section 1847A(i)(5) of the Act requires that for Part B rebatable drugs, as defined in section 1847A(i)(2)(A) of the Act, furnished on or after April 1, 2023, in quarters in which the payment amount described in section 1847A(i)(3)(A)(ii)(I) of the Act (or, in the case of selected drugs described under section 1192(c) of the Act, the payment amount described in section 1847A(b)(1)(B) of the Act), exceeds the inflation-adjusted payment amount determined in accordance with section 1847A(i)(3)(C) of the Act, the coinsurance will be 20 percent of the inflation-adjusted payment amount for such quarter (hereafter, the inflation-adjusted coinsurance amount)
Wound Care and Regenerative Medicine GHK-Cus wound-healing properties are being explored for: Burns Chronic wounds Surgical incisions Diabetic ulcers and pressure sores Topical GHK-Cu may be used in advanced dressings and ointments to stimulate angiogenesis, reduce inflammation, and promote faster closure (Maquart et al., 1993)
Safety analysis Cardiovascular monitoring, heart rate increases, adverse event reporting
Hortic Res
%20(1).png)
